Major Study Of BSD Medical's Cancer Therapy In Combination With Chemotherapy Highlighted In ASCO News And In Summary Session

BSD Medical Corp.
(Amex: BSM) reported today that the follow-up reviews of the presentation
of results from a 340 patient randomized Phase III clinical trial testing
the benefit of adding hyperthermia therapy to chemotherapy were both
positive and enthusiastic at the American Society of Clinical Oncology
(ASCO) conference, concluding in Chicago, Illinois. This year's ASCO was
attended by over 30,000 participants who specialize in clinical oncology.
In his review of the study, quoted by the ASCO Daily News, Dr. Fredrick C.
Eilber of UCLA called the "collaborative study 'impressive' and considers
it a 'tremendous effort' to find better treatment options for a disease
that is often fatal with local recurrence."


Several phase III clinical studies have shown significantly better
results in treating certain cancers when hyperthermia therapy was added to
radiation therapy, as compared to radiation treatments alone. Rolf D.
Issels, MD PhD, who presented the results of this new study at ASCO,
underscored the importance of this new study by explaining, "This is the
first randomized phase III clinical trial ever conducted on the use of
regional hyperthermia therapy in combination with standard chemotherapy. It
showed an approximate doubling of disease-free survival and local
progression-free survival for high risk soft tissue sarcoma patients when
hyperthermia therapy was added to chemotherapy, as compared to the results
for patients treated with chemotherapy alone."




While presenting the results of the study, Dr. Issels used a slide
showing a patient being treated with a BSD-2000 by BSD Medical Corp. to
accompany his statement: "The take-home message is that precise targeting
of regional hyperthermia can now be routinely applied to patients with
locally-advanced, high-grade soft tissue sarcoma." Results of the study
were formally presented at ASCO June 4 and were summarized again June 5 in
a general session of meeting highlights by Robert G. Maki, MD PhD, of
Memorial Sloan-Kettering Cancer Center.



The use of precision-focused mild heating of cancer (hyperthermia
therapy) during chemotherapy treatments opens cancer cells to better
absorption of chemotherapy drugs by improving blood flow as well as by
other biological mechanisms of action. Hyperthermia therapy also kills
cancer cells directly and can be used to improve chemical reactions of some
chemotherapy drugs.



This clinical study was sponsored by both the EORTC (European
Organization for Research and Treatment of Cancer) and ESHO (European
Society for Hyperthermic Oncology). Professor Rolf Issels, MD PhD of the
Klinikum Grosshadern Medical Center at the University of Munich, Munich,
Germany was principal investigator and presenter of the study results. The
study is listed by the National Cancer Institute as NCI number NCT00003052.
This clinical trial was supported by German Cancer Aid and the Association
of German Research Centers.



All hyperthermia treatments performed in the study were conducted using
BSD-2000 hyperthermia systems developed and produced by BSD Medical Corp.
The BSD-2000 hyperthermia therapy system non-invasively delivers precision
focused hyperthermia therapy to cancerous tumors, including tumors located
deep in the body.



About BSD Medical



BSD Medical Corp. is a leading developer of systems used to deliver
therapies involving precision-focused heat for the treatment of cancer. The
objective of the company is to deliver a complete solution in thermal
treatments for cancer, as provided by precision-focused microwave heating,
to support radiation oncologists, interventional radiologists, medical
oncologists and surgeons in providing more effective procedures and
treatments. For further information visit BSD Medical's website at
BSDMedical or BSD's patient website at
treatwithheat.



Statements contained in this press release that are not historical
facts are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are subject
to risks and uncertainties detailed in the Company's filings with the
Securities and Exchange Commission.


BSD Medical Corp.

BSDMedical